MP16-05 COMPARISON OF PROSTATE HEALTH INDEX (PHI) AND MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING (MRI) IN DETECTION OF CLINICALLY-SIGNIFICANT PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Detection & Screening I1 Apr 2016MP16-05 COMPARISON OF PROSTATE HEALTH INDEX (PHI) AND MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING (MRI) IN DETECTION OF CLINICALLY-SIGNIFICANT PROSTATE CANCER Alexander Glaser, Phillip Cooper, Kimberly Roehl, and William Catalona Alexander GlaserAlexander Glaser More articles by this author , Phillip CooperPhillip Cooper More articles by this author , Kimberly RoehlKimberly Roehl More articles by this author , and William CatalonaWilliam Catalona More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2570AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The Prostate Health Index (PHI) and multiparametric magnetic resonance imaging (MRI) are among newer methods to improve the detection of clinically-significant prostate cancer (PCa). We studied the performance of PHI and MRI in detection of Gleason ≥7 PCa in 103 men who underwent PHI testing and multiparametric MRI for evaluation of an elevated PSA ≥2 ng/mL. METHODS We categorized MRI as into three categories: 1) not suspicious for PCa, 2) indeterminate, and 3) suspicious for PCa. We categorized PHI scores into the four risk categories recommended by the manufacturer. PHI and MRI risk categories were compared using Pearson's correlation. In the 66 men who underwent PNB, receiver operating characteristic (ROC) analysis was performed to compare the test characteristics of PHI and MRI in detecting Gleason ≥7 PCa. RESULTS Demographics, clinical characteristics, PHI and MRI results are shown in Table 1. PHI scores in the highest two risk categories and MRI suspicious for PCa did not significantly correlate (r=0.11, p=0.25). Outcomes of the ROC analysis are shown in Figure 1. The area under the curve (AUC) for PHI was 0.70 (95% CI 0.57-0.82). The AUC for MRI was 0.74 (95% CI 0.63-0.84). The largest AUC, 0.84 (95% CI 0.73-0.94), was obtained by combining MRI with PHI. CONCLUSIONS We conclude that PHI and MRI in combination have superior diagnostic performance in detecting clinically-significant prostate cancer compared with either test alone. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e162-e163 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Alexander Glaser More articles by this author Phillip Cooper More articles by this author Kimberly Roehl More articles by this author William Catalona More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...